Structural basis of l-tryptophan-dependent inhibition of release factor 2 by the TnaC arrest peptide - PubMed In Escherichia coli, elevated levels of free l-tryptophan (l-Trp) promote translational arrest of the TnaC peptide by inhibiting its termination. However, the mechanism by which translation-termination by the UGA-specific decoding release factor 2 (RF2) is inhibited at the UGA stop codon of stalled …

The cryo-EM structure of a TnaC–ribosome complex shows how L-tryptophan stalls translation via a sequence-specific pocket in the exit tunnel (pubmed.ncbi.nlm.nih.gov/34403461) 
This is in prokaryotes but I’d bet the mechanism exists in eukaryotes.
#biotech #drugdiscovery #cryoEM #blueskybiotech

#blueskybiotech

UCLA scientists reprogram stem cells to create renewable cancer-fighting T cells In a first-of-its-kind clinical trial, UCLA scientists have shown it’s possible to reprogram a patient’s blood-forming stem cells to generate a continuous supply of functional T cells, the immune syst...

CIRM-funded @uclastemcell.bsky.social researchers reprogrammed blood #StemCells to produce #cancer-targeting T cells—offering a renewable path for immunotherapy. Early results are promising for treatment-resistant tumors.

#BlueskyBiotech

Thank you to all the incredible trainees, program directors, patient advocates, and inspiring speakers who joined us for the 2025 #CIRMTraineeConference!

We’re grateful for the insights you shared and the community we continue to build together in advancing #RegenerativeMedicine. #BlueskyBiotech

20 Years of CIRM: Building the Workforce In celebration of the California Institute for Regenerative Medicine (CIRM)’s 20th anniversary, we have been reflecting on some of the early projects we supported and their outcomes.Today, we’re lo…

CIRM supports hands-on research training for students of all education levels. These highly trained students help power California’s $414 billion #LifeSciences industry and bring new treatments closer to patients.

Learn more about how we’re investing in people, and not just science. #BlueskyBiotech

Millions live with painful osteoarthritis worldwide. A CIRM-funded clinical trial by Genascence reported positive early results using a gene therapy approach, demonstrating safety and sustained efficacy at 12 months.

Learn more on our blog at bit.ly/4nzlpzb

#BlueskyBiotech #Science #ClinicalTrials

Promotional graphic with a photograph of Jonathan Betts.

Entrepreneurs on the Move 💡

Jonathan will share his insights and experience in the challenges of commercializing tech, building sustainable scientific businesses, and leading through change in mission-driven organizations.

🔗 lnkd.in/e7U9wZvw

#BlueskyBiotech

Backed by a $14 million CIRM award, Neurona Therapeutics is advancing a stem cell therapy that could transform epilepsy treatment without surgery or tissue damage. Learn more on our blog: blog.cirm.ca.gov/2025/06/20/n...

#neuroskyence #blueskybiotech #epilepsy #regenerativemedicine

Promotional graphic for a blog post showing a graphic representation of the split between small molecules, proteins and oligonucleotides plus the 3D structure of CSD refcode POHPEL.

💡The #FDA approved 50 new drugs in 2024, 64% of which were #SmallMolecules.

Find out more about the novel drug approval trends from the past 5 years and discover the structures of the small molecule drugs that are in the CSD 👉🔗 ccdc-info.com/3WIJWWz

#Pharmaceuticals #ChemSky #BlueskyBiotech

Ever wonder how biomedical innovation actually works (or doesn’t?)

When everyone has an opinion about healthcare costs, and specifically drug prices, it helps to know how drugs happen.

#biosky #blueskybiotech